Background. Solitary metastasis of renal cell carcinoma in the pituitary
Introduction
Renal cell carcinoma is the most common primary tumour of the kidney accounting 1 -3% of all adult malignancies. 1 Although brain is the fourth most common site of metastasis after lung, bone and liver with approximately 5% 1 , solitary metastasis of renal cell carcinoma in the pituitary gland is extremely rare. [1] [2] [3] [4] [5] [6] The frequency of pituitary metastases from systemic malignant tumours ranged from 1% to 25% at autopsy. 7 Only 7% of pituitary metastases are symptomatic. 2 Pituitary metastases occur usually in patients with highly disseminated disease. Breast and lung cancer are the most common diseases that metastasize to the pituitary gland. 2, 6 Case report
We present the case of a patient diagnosed with a pituitary gland metastatic renal cell carcinoma after three years of treatment due to the metastatic disease. In August 2003, a 49 year old man presented with tumour of the lower part of the left kidney. Left nephrectomy was performed. Pathology confirmed clear cell carcinoma, tumour stage T3bN0M0. During his first postoperative visit to the oncological department multiple bilateral lung metastases smaller than 1 cm in diameter were found along with osteolysis of the posterior part of the forth right rib. Patient ECOG score was 0. Since interferon and interleukin-2 were not registered for the treatment of metastatic renal cell carcinoma in Croatia, his treatment was started with chemotherapy -vinblastin 6 mg/m 2 (Figures 1a, 1b) .
Since visual function deteriorated progressively, a trans-sphenoidal surgery was performed. Pathology and imunohistology revealed metastasis of clear cell renal carcinoma.
The visual function was quickly improved but Goldmann test (Figures 2a, 2b) showed still disturbances in the visual function. Endocrinological findings were almost consistent with panhypopituitarism: T4 = 80. Postoperative control MRI after two months showed residual tumour 20x13x12 mm in diameter but now along with multiple brain metastases. The palliative brain photon beam radiotherapy was performed, total dose 30 Gy in 10 fractions. CT scan of thorax and abdomen revealed the progression of the lung metastases and the occur- rence of new bone metastases. Surprisingly, the patient was without respiratory disturbances but he reported fatigue. His general appearance was Cushingoidal. He died ten months after the operation of the pituitary gland.
Discussion
Up to our knowledge only 24 cases of symptomatic pituitary metastasis of renal cell carcinoma has been reported in the literature (Table 1) . Only six of them were female, while 18 were men. The majority i.e. 19 patients presented with hypopituitarism, while 17 patients presented with visual field defect like our patient. Our patient has not experienced symptoms of diabetes insipidus which is reported to be more frequent in pituitary metastasis than in pituitary adenomas. 7, 21 It is very difficult to differentiate pituitary metastasis from adenoma based on radiological and clinical findings. 2, 3, 10, 12, 22 But Liu et al. 7 found out that the strong enhancement of the tumour and the strong bone destruction without marked sellar enlargement are characteristic radiological features of pituitary metastasis. Fassett et al. 2 stated that thickening of the pituitary stalk, invasion of the cavernous sinus and sclerosis of the surrounding sella turcica could indicate pituitary metastasis. Tumour invasiveness usually makes the resection difficult. There was no significant survival benefit in surgical series. 2 The treatment of pituitary metastasis is multimodal, consisting of surgery, radiotherapy and chemotherapy. The long-term benefit of postoperative radiotherapy is not known due to the rarity of such cases. The applied dose ranged in the literature from 9 to 60 Gy, with median dose 36 Gy. 6 Our patient was treated with 30 Gy in ten fractions due to the occurrence of brain metastases although first it was intended to apply a higher dose. Stereotactic radiotherapy can be beneficial in sparing the optic nerves. The primary aim of treating pituitary metastasis is to improve the quality of life through symptomatic relief and to prevent the neurological deterioration.
The overall median length of the patient's survival after the diagnosis of pituitary metastasis is only 180 days. 6 However, the paper recently published by Gopan et al. 20 reported the overall survival ranging from 6 to 46 months from the initial diagnosis of pituitary metastasis. This can be explained by the application of new chemotherapeutic agents like sorafenib and sunitinib. Stereotactic radiotherapy with or without whole brain radiotherapy was performed in all five reported patients.
In our case, whole brain radiotherapy was performed due to the brain dissemination. Sorafenib and sunitinib were not registered for the treatment of metastatic renal cell carcinoma in our country at the time.
Symptomatic pituitary metastasis of renal cell carcinoma is a rare case, occurring usually in highly disseminated renal cell carcinoma. Palliative surgery and radiotherapy treatment can contribute essentially to the improvement of the quality of life of such patients.
